The new emphasis on assessing cardiovascular risk for diabetes patients is the latest turn in the FDA’s focus on diabetes drug development. To help you identify the full implications of the 2008 FDA Guidance on antidiabetic therapies on your development plans, two of our top experts in diabetes and cardiac safety have teamed up to take a closer look at the FDA’s recommendations. You’ll find their insights on everything from study design to endpoints will help you fine-tune your next diabetes clinical trial.